Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer

American Journal of Pathology

Volumn 184, Issue 12, 2014, Pages 3217-3225

  Mackenzie, Todd A ^a   Schwartz, Gary N ^a   Calderone, Heather M ^b   Graveel, Carrie R ^b   Winn, Mary E ^b   Hostetter, Galen ^b   Wells, Wendy A ^a   Sempere, Lorenzo F ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA 21; PROGESTERONE RECEPTOR; SMALL NUCLEAR RNA; ERBB2 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FLUORESCENCE MICROSCOPY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; NORTHERN BLOTTING; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; STROMA; TRIPLE NEGATIVE BREAST CANCER; AGED; CELL SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STROMA CELL;

AGED; CELL SURVIVAL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; STROMAL CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84913582144     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.08.020     Document Type: Article

References (58)

1. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
2. C. Curtis, S.P. Shah, S.F. Chin, G. Turashvili, O.M. Rueda, M.J. Dunning, D. Speed, A.G. Lynch, S. Samarajiwa, Y. Yuan, S. Graf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney, A. Langerod, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A.L. Borresen-Dale, J.D. Brenton, S. Tavare, C. Caldas, and S. Aparicio The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 486 2012 346 352
3. J.M. Bartlett, K.J. Bloom, T. Piper, T.J. Lawton, dV. van, D.T. Ross, B.Z. Ring, R.S. Seitz, R.A. Beck, A. Hasenburg, D. Kieback, H. Putter, C. Markopoulos, L. Dirix, C. Seynaeve, and D. Rea Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study J Clin Oncol 30 2012 4477 4484
4. S.J. Schnitt Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy Mod Pathol 23 Suppl 2 2010 S60 S64
5. M. Yan, B.A. Parker, R. Schwab, and R. Kurzrock HER2 aberrations in cancer: implications for therapy Cancer Treat Rev 40 2014 770 780
6. F.M. Blows, K.E. Driver, M.K. Schmidt, A. Broeks, F.E. van Leeuwen, and J. Wesseling Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies PLoS Med 7 2010 e1000279
7. S. Bayraktar, and S. Gluck Molecularly targeted therapies for metastatic triple-negative breast cancer Breast Cancer Res Treat 138 2013 21 35
8. S. Kashiwagi, M. Yashiro, T. Takashima, N. Aomatsu, K. Ikeda, Y. Ogawa, T. Ishikawa, and K. Hirakawa Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67 Breast Cancer Res 13 2011 R122
9. O. Engebraaten, H.K. Vollan, and A.L. Borresen-Dale Triple-negative breast cancer and the need for new therapeutic targets Am J Pathol 183 2013 1064 1074
10. I.A. Mayer, V.G. Abramson, B.D. Lehmann, and J.A. Pietenpol New strategies for triple-negative breast cancer: deciphering the heterogeneity Clin Cancer Res 20 2014 782 790
11. G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, H. Zhao, H. Chen, G. Omeroglu, S. Meterissian, A. Omeroglu, M. Hallett, and M. Park Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 2008 518 527
12. P. Farmer, H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, V. Becette, S. Andre, M. Piccart, M. Campone, E. Brain, G. Macgrogan, T. Petit, J. Jassem, F. Bibeau, E. Blot, J. Bogaerts, M. Aguet, J. Bergh, R. Iggo, and M. Delorenzi A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 2009 68 74
13. E.M. de Kruijf, J.G. van Nes, C.J. van de Velde, H. Putter, V.T. Smit, G.J. Liefers, P.J. Kuppen, R.A. Tollenaar, and W.E. Mesker Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients Breast Cancer Res Treat 125 2011 687 696
14. J.T. Mendell, and E.N. Olson MicroRNAs in stress signaling and human disease Cell 148 2012 1172 1187
15. A. Ventura, and T. Jacks MicroRNAs and cancer: short RNAs go a long way Cell 136 2009 586 591
16. Sempere LF, Kauppinen S: Translational Implications of MicroRNAs in Clinical Diagnostics and Therapeutics: Handbook of Cell Signaling. Edited by RA Bradshaw, EA Dennis. Oxford, Academic Press, 2009, pp 2965-2981
17. S.P. Nana-Sinkam, and C.M. Croce Clinical applications for microRNAs in cancer Clin Pharmacol Ther 93 2013 98 104
18. R. Garzon, G. Marcucci, and C.M. Croce Targeting microRNAs in cancer: rationale, strategies and challenges Nat Rev Drug Discov 9 2010 775 789
19. H. Ling, M. Fabbri, and G.A. Calin MicroRNAs and other non-coding RNAs as targets for anticancer drug development Nat Rev Drug Discov 12 2013 847 865
20. L.F. Sempere Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer Expert Rev Mol Diagn 11 2011 813 827
21. L.F. Sempere Recent advances in miRNA-based diagnostic applications Expert Rev Mol Diagn 12 2012 557 559
22. J. Radojicic, A. Zaravinos, T. Vrekoussis, M. Kafousi, D.A. Spandidos, and E.N. Stathopoulos MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer Cell Cycle 10 2011 507 517
23. D. Ota, K. Mimori, T. Yokobori, M. Iwatsuki, A. Kataoka, N. Masuda, H. Ishii, S. Ohno, and M. Mori Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients Int J Oncol 38 2011 955 962
24. C. Gong, Y. Yao, Y. Wang, B. Liu, W. Wu, J. Chen, F. Su, H. Yao, and E. Song Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer J Biol Chem 286 2011 19127 19137
25. B. Qian, D. Katsaros, L. Lu, M. Preti, A. Durando, R. Arisio, L. Mu, and H. Yu High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1 Breast Cancer Res Treat 117 2009 131 140
26. L.X. Yan, X.F. Huang, Q. Shao, M.Y. Huang, L. Deng, Q.L. Wu, Y.X. Zeng, and J.Y. Shao MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis RNA 14 2008 2348 2360
27. J.A. Lee, H.Y. Lee, E.S. Lee, I. Kim, and J.W. Bae Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast J Breast Cancer 14 2011 269 275
28. N. Anastasov, I. Hofig, I.G. Vasconcellos, K. Rappl, H. Braselmann, N. Ludyga, G. Auer, M. Aubele, and M.J. Atkinson Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells Radiat Oncol 7 2012 206
29. P.P. Medina, M. Nolde, and F.J. Slack OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma Nature 467 2010 86 90
30. M.E. Hatley, D.M. Patrick, M.R. Garcia, J.A. Richardson, R. Bassel-Duby, R.E. van, and E.N. Olson Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21 Cancer Cell 18 2010 282 293
31. B.E. Kadera, L. Li, P.A. Toste, N. Wu, C. Adams, D.W. Dawson, and T.R. Donahue MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis PLoS One 8 2013 e71978
32. M.D. Bullock, K.M. Pickard, B.S. Nielsen, A.E. Sayan, V. Jenei, M. Mellone, R. Mitter, J.N. Primrose, G.J. Thomas, G.K. Packham, and A.H. Mirnezami Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression Cell Death Dis 4 2013 e684
33. A.C. Chung, X. Yu, and H.Y. Lan MicroRNA and nephropathy: emerging concepts Int J Nephrol Renovasc Dis 6 2013 169 179
34. Y. Cheng, and C. Zhang MicroRNA-21 in cardiovascular disease J Cardiovasc Transl Res 3 2010 251 255
35. L.F. Sempere, M. Preis, T. Yezefski, H. Ouyang, A.A. Suriawinata, A. Silahtaroglu, J.R. Conejo-Garcia, S. Kauppinen, W. Wells, and M. Korc Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors Clin Cancer Res 16 2010 4246 4255
36. P.T. Nelson, and B.R. Wilfred In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain Neurosci Lett 466 2009 69 72
37. X. Zhang, X. Lu, G. Lopez-Berestein, A. Sood, and G. Calin In situ hybridization-based detection of microRNAs in human diseases microRNA Diagn Ther 1 2013 12 23
38. B.S. Nielsen, and K. Holmstrom Combined microRNA in situ hybridization and immunohistochemical detection of protein markers Methods Mol Biol 986 2013 353 365
39. B.S. Nielsen, S. Jorgensen, J.U. Fog, R. Sokilde, I.J. Christensen, U. Hansen, N. Brunner, A. Baker, S. Moller, and H.J. Nielsen High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients Clin Exp Metastasis 28 2011 27 38
40. L.F. Sempere, M. Christensen, A. Silahtaroglu, M. Bak, C.V. Heath, G. Schwartz, W. Wells, S. Kauppinen, and C.N. Cole Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer Cancer Res 67 2007 11612 11620
41. S. Jorgensen, A. Baker, S. Moller, and B.S. Nielsen Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes Methods 52 2010 375 381
42. L. Rask, E. Balslev, S. Jorgensen, J. Eriksen, H. Flyger, S. Moller, E. Hogdall, T. Litman, and N.B. Schnack High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer APMIS 119 2011 663 673
43. D.G. Altman, L.M. McShane, W. Sauerbrei, and S.E. Taube Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration PLoS Med 9 2012 e1001216
44. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
45. L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, G. Karaca, M.A. Troester, C.K. Tse, S. Edmiston, S.L. Deming, J. Geradts, M.C. Cheang, T.O. Nielsen, P.G. Moorman, H.S. Earp, and R.C. Millikan Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2006 2492 2502
46. E.A. Rakha, J.S. Reis-Filho, F. Baehner, D.J. Dabbs, T. Decker, V. Eusebi, S.B. Fox, S. Ichihara, J. Jacquemier, S.R. Lakhani, J. Palacios, A.L. Richardson, S.J. Schnitt, F.C. Schmitt, P.H. Tan, G.M. Tse, S. Badve, and I.O. Ellis Breast cancer prognostic classification in the molecular era: the role of histological grade Breast Cancer Res 12 2010 207
47. S. Volinia, G.A. Calin, C.G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R.L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C.C. Harris, and C.M. Croce A microRNA expression signature of human solid tumors defines cancer gene targets Proc Natl Acad Sci U S A 103 2006 2257 2261
48. R. Kumarswamy, I. Volkmann, and T. Thum Regulation and function of miRNA-21 in health and disease RNA Biol 8 2011 706 713
49. C.M. Perou, T. Sorlie, M.B. Eisen, R.M. van de, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. Borresen-Dale, P.O. Brown, and D. Botstein Molecular portraits of human breast tumours Nature 406 2000 747 752
50. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, R.M. van de, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, L.P. Eystein, and A.L. Borresen-Dale Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
51. V.N. Kristensen, C.J. Vaske, J. Ursini-Siegel, L.P. Van, S.H. Nordgard, R. Sachidanandam, T. Sorlie, F. Warnberg, V.D. Haakensen, A. Helland, B. Naume, C.M. Perou, D. Haussler, O.G. Troyanskaya, and A.L. Børresen-Dale Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling Proc Natl Acad Sci U S A 109 2012 2802 2807
52. B. Kreike, M. van Kouwenhove, H. Horlings, B. Weigelt, H. Peterse, H. Bartelink, and M.J. van de Vijver Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas Breast Cancer Res 9 2007 R65
53. B.D. Lehmann, J.A. Bauer, X. Chen, M.E. Sanders, A.B. Chakravarthy, Y. Shyr, and J.A. Pietenpol Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2011 2750 2767
54. S. Kjaer-Frifeldt, T.F. Hansen, B.S. Nielsen, S. Joergensen, J. Lindebjerg, F.B. Soerensen, C.R. dePont, and A. Jakobsen The prognostic importance of miR-21 in stage II colon cancer: a population-based study Br J Cancer 107 2012 1169 1174
55. L.E. Buscaglia, and Y. Li Apoptosis and the target genes of microRNA-21 Chin J Cancer 30 2011 371 380
56. Y. Yuan, H. Failmezger, O.M. Rueda, H.R. Ali, S. Graf, S.F. Chin, R.F. Schwarz, C. Curtis, M.J. Dunning, H. Bardwell, N. Johnson, S. Doyle, G. Turashvili, E. Provenzano, S. Aparicio, C. Caldas, and F. Markowetz Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling Sci Transl Med 4 2012 157ra43
57. A.H. Beck, A.R. Sangoi, S. Leung, R.J. Marinelli, T.O. Nielsen, dV. van, R.B. West, R.M. van de, and D. Koller Systematic analysis of breast cancer morphology uncovers stromal features associated with survival Sci Transl Med 3 2011 108ra13
58. A.M. Moorman, R. Vink, H.J. Heijmans, P.J. van der, and E.A. Kouwenhoven The prognostic value of tumour-stroma ratio in triple-negative breast cancer Eur J Surg Oncol 38 2012 307 313